

Curriculum Vitae and Bibliography

Robert F. Marschke, Jr., M.D.

PERSONAL INFORMATION

Date of Birth: February 15, 1949
Place of Birth: Indianapolis, IN
Citizenship: United States of America

PRESENT ADDRESS:

Front Range Cancer Specialists Phone: (970) 212-7600
2315 E Harmony Road, Suite 110 Fax: (970) 212-7612
Fort Collins, CO 80528

PRESENT ACADEMIC RANK AND POSITION

Active Medical Staff - Poudre Valley Hospital, Fort Collins, Colorado 1996 - Present
Physician Consultant - Front Range Cancer Specialists, Fort Collins, Colorado Present
Physician Consultant - Division of Hematology/Oncology 1987 - 1996 and
Department of Internal Medicine, Mayo Clinic 2003 - 2007
Associate Professor of Medicine - Mayo Clinic College of Medicine 1996 - 2007

EDUCATION

University of Wisconsin, Madison, WI; Bachelor of Science 1967 - 1971
University of South Dakota, Vermillion, SD; Master of Science 1971 - 1973
Baylor College of Medicine, Houston, TX; MD, with honors 1973 - 1975
Mayo Clinic Rochester, Residency, Internal Medicine 1975 - 1978
Mayo Clinic Rochester, Fellowship, Medical Oncology 1978 - 1980

BOARD CERTIFICATION(S)

American Board of Internal Medicine Diplomate in Internal Medicine 1978
Certificate 66897 9/13/78
American Board of Internal Medicine Diplomate in Medical Oncology 1981
Certificate 66897 11/10/81

LICENSURE

Arizona
 Colorado
 Wyoming

HONORS/AWARDS

Wisconsin Alumni Scholarship	1967
Eugene Pulliam Scholarship	1967
Edwin Shaw Award for Excellence in Biochemistry	1973
Alpha Omega Alpha	1975
American Cancer Society Fellowship Award	1979 - 1980

PREVIOUS PROFESSIONAL POSITIONS AND MAJOR APPOINTMENTS

Instructor of Oncology - Mayo Medical School	1978 - 1980
Clinical Assistant Professor of Medicine - University of South Dakota School of Medicine	1980 - 1985
Physician Consultant - Central Plains Clinic, Sioux Falls, South Dakota	1980 - 1987
Active Medical Staff - Sioux Valley Hospital, Sioux Falls, South Dakota	1980 - 1987
Active Medical Staff - McKennan Hospital, Sioux Falls, South Dakota	1980 - 1987
Director of Oncology - McKennan Hospital	1981 - 1983
Consultant - Royal C. Johnson Memorial VAMC	1985
Clinical Associate Professor of Medicine - University of South Dakota School of Medicine	1985 - 1987
Active Medical Staff - Scottsdale Memorial Hospital North, Scottsdale, Arizona	1987 - 1996
Physician Consultant - Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic	1987 - 1996
Chair - Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic	1988 - 1995
Assistant Professor of Oncology - Mayo Medical School	1987 - 1996
Associate Professor of Oncology - Mayo Medical School	1996
Oncology Medical Director - Poudre Valley Hospital	1996 - 1998
Chairman - Cancer Committee, Poudre Valley Hospital, Fort Collins, Colorado	1997 - 1999
Physician Consultant - Hematology/Oncology Associates, P.C., Fort Collins, Colorado	1999 - 2003
Physician Consultant - Rocky Mountain Cancer Centers - Northern Colorado, Fort Collins, Colorado	1999 - 2003

PROFESSIONAL & COMMUNITY MEMBERSHIPS, SOCIETIES AND SERVICES
(*indicates office held)

Professional Memberships & Services

American Board of Internal Medicine

*Diplomate 1978

Medical Oncology

*Diplomate 1982

American College of Physicians

*Member 1982

American Society of Clinical Oncology

*Member

Colorado Medical Society

*Delegate 1997 - 2002

*Member 1997 - 2002

Eastern Cooperative Oncology Group

*Member 1987 - Present

Thoracic Committee

*Member 1994 - 1996

International Association for the Study of Lung Cancer

*Member

Larimer County Medical Society

*Member

*Delegate 1997 - 1998

Mayo Clinic Hospital

*Medical Staff 2003 - Present

National Board of Medical Examiners

*Diplomate 1976

National Institutes of Health

National Cancer Institute

Lung Cancer Working Cadre

*Member 1994 - 1996

North Central Cancer Treatment Group

*Sioux Falls Representative 1981 - 1987

*Member 1987 - Present

*Scottsdale Representative 1993 - 1996

Executive Committee

*Member 1987 - Present

Oncology Research Committee

RMCC Division
*Member 1999 - 2003

Poudre Valley Hospital
Institutional Review Board
*Member 1996 - 2003

EDUCATIONAL ACTIVITIES

Teaching

Management of advanced breast cancer & breast cancer adjuvant therapy Internal medicine grand rounds, USD School of Medicine McKenna Hospital Auditorium Sioux Falls, South Dakota	02/03/1982
Emergencies in medical oncology 60-minute presentation to Department of Internal Medicine medical grand rounds, 7:30 a.m. to 8:30 a.m., questions moderated thereafter by Robert C. Talley, M.D. USD School of Medicine	03/20/1985
Adjuvant cancer therapy medical grand rounds (travel expenses and honorarium) USD School of Medicine, McKenna Hospital Sioux Falls, South Dakota	04/06/1988
Cancer Reviews Course Director Mayo Clinic Scottsdale Scottsdale, Arizona	1989 - 1991
Hematology and Oncology for the Primary Care Physician Course Director Mayo Clinic Scottsdale Scottsdale, Arizona	1989 - 1991
Care of the terminally ill patient MIMS Lecture	08/22/1991
When should cancer NOT be treated also given as a Friday morning conference topic later in 1991 MIMS Lecture Scottsdale, Arizona	10/28/1991
Care of the terminally ill patient MIMS Lecture	12/09/1991
When should cancer NOT be treated presentation to transitional year and internal medicine residents Scottsdale Memorial Hospital - North Scottsdale, Arizona	01/06/1992
Care of the terminally ill patient presentation to transitional year and internal medicine residents Scottsdale Memorial Hospital - North Scottsdale, Arizona	03/09/1992
When should cancer NOT be treated presentation to transitional year and internal medicine residents Scottsdale Memorial Hospital - North Scottsdale, Arizona	05/15/1992

When should cancer NOT be treated presentation to transitional year and internal medicine residents Scottsdale Memorial Hospital - North Scottsdale, Arizona	08/27/1992
Bone marrow transplantation Hematology/Oncology Medical Secretaries	09/1992
When should cancer NOT be treated presentation to transitional year and internal medicine residents Scottsdale Memorial Hospital - North Scottsdale, Arizona	12/07/1992

INSTITUTIONAL/DEPARTMENTAL ADMINISTRATIVE RESPONSIBILITIES, COMMITTEE MEMBERSHIPS AND OTHER ACTIVITIES (* indicates office held)

Cancer Center, Clinical Research Working Group
*Member 2003 - Present

Institutional Review Board
*Member 1995 - 1996

Mayo Medical School
Admissions Committee 1978 - 1980

Scottsdale Committees
Research Committee
*Member 1987 - 1995
*Vice Chair 1992 - 1995
Planning Committee
*Chair 1991
Development Liaison Committee
*Chair 1992
Project Delta
*Chair 1994

Scottsdale Memorial Hospital North
Pharmacy and Therapeutics Committee
*Chairman 1994 - 1996
Institutional Review Board
*Member 1992 - 1996
Bone Marrow Transplantation Committee
*Chairman 1992 - 1994

PRESENTATIONS

International

Sarcoidosis and malignant neoplasms Mayo Alumni Meeting Montreal, Canada	10/03/1981
Management of the patient with cancer of unknown primary	05/01/1993

Mayo Alumni Association International Meeting
Nashville, Tennessee

National

Management of small cell lung carcinoma Central Plains Clinic Symposium	04/1980
Cerebral metastases Tumor Conference, Sioux Valley Hospital	09/10/1980
Hormonal therapy of breast cancer District Medical Meeting Storm Lake, Iowa	09/28/1980
Diagnostic radiology as applied to medical oncology Annual Convention of Radiology Technicians Sioux Falls, South Dakota	10/18/1980
Management of non-Hidgkin's lymphoma Southwestern Minnesota District Medical Society Worthington, Minnesota	02/02/1981
Management of metastatic breast cancer District Medical Society Meeting Aberdeen, South Dakota	04/01/1981
Management of small cell lung carcinoma CPC Symposium	04/11/1981
Sarcoidosis and malignant neoplasm State Medical Association	06/1981
Breast cancer adjuvant treatment & management of recurrent and metastatic breast cancer American College of Physicians Rapid City, South Dakota	09/12/1981
Management of ovarian carcinoma McKenna Hospital Mayo outreach seminar	10/23/1981
Common cancer screening recommendations CPC Symposium Sioux Falls, South Dakota	03/26/1982
Modern day cancer chemotherapy Sioux Valley Hospital Nursing Alumni Sioux Falls, South Dakota one hour lecture	05/04/1982
Dermatological manifestations of malignant neoplasms CPC Symposium	03/18/1983
Cancer from the perspective of a medical oncologist American Cancer Society I Can Cope meeting - 90 minute session	03/19/1984
Annual Oncology-Hematology Symposium	04/27/1984
Metastatic bone cancer Annual Oncology-Hematology Symposium 30-minute discussion	04/28/1984
Nonsurgical management of lung cancer North Central Heart Symposium, Ramada Inn Sioux Falls, South Dakota	10/05/1984

Cancer prevention, an oncologist's viewpoint and Cancer prevention, it's up to you jointly sponsored by Sioux Valley Hospital, Sioux Falls College and the American Cancer Society	10/06/1984
DNA repair deficiency syndromes, the oncogeny and hereditary cancer, and Cancer chemotherapy University of South Dakota School of Medicine Department of Biochemistry Vermillion, South Dakota	10/29/1984
Management of simultaneous breast adenocarcinoma and multiple myeloma American College of Physicians Meeting Pierre, South Dakota	09/06/1985
Randomized trial of CAV with or without VP-16 for limited disease small cell lung cancer 22nd Annual Meeting, American Society of Clinical Oncology Los Angeles, California poster presentation	05/04/1986 - 05/06/1986
A phase II trial of bisantrene administered by 72 hour infusion for advanced measurable pancreatic carcinoma 77th Annual Meeting, American Association for Cancer Research Los Angeles, California poster presentation	05/07/1986 - 05/10/1986
A comparison of CFP and CMFP chemotherapy in women with advanced breast cancer American Society of Clinical Oncology Meeting New Orleans, Louisiana	05/24/1988
Adjuvant therapy in common malignancies and Care of the terminally ill cancer patient Mayo Continuing Education Course San Diego, California selected topics in internal medicine	02/18/1991 - 02/19/1991
I can cope American Cancer Society	05/06/1992
Management of cancer of unknown primary source Hematology/Oncology Update Current Issues and Controversies Amelia Island, Florida	09/11/1994
Percutaneous ethanol injection therapy for malignant hepatic neoplasms Hematology/Oncology Update Current Issues and Controversies Amelia Island, Florida	09/13/1994
Colorectal cancer adjuvant therapy Hematology/Oncology Update Current Issues and Controversies Amelia Island, Florida	09/15/1994
Randomized phase II trial of two schedules of topotecan for the treatment of advanced stage nonsmall cell lung carcinoma: a North Central Cancer Treatment Group Trial American Society of Clinical Oncology Meeting Los Angeles, California 35 mm slide presentation	05/1995
Phase II trial of high dose somatostatin analogue in previously untreated patients with extensive stage small cell lung carcinoma: a North Central Cancer Treatment Group Trial American Society of Clinical Oncology Meeting Los Angeles, California	05/1995

poster presentation

State of the art management of small-cell lung carcinoma 08/19/1995
Fifth Annual Hematology/Oncology Reviews
Mayo Clinic Jacksonville

The history of cancer chemotherapy 03/04/1997
North Central Cancer Treatment Group Clinical Research Associate and
Registered Oncology Nursing Workshop
Rochester, Minnesota
35 mm slide presentation, Siebens Building, Mayo Clinic Rochester

Diet, vitamins, nutrition and cancer 03/08/1997
Hematology and Oncology Reviews
Phoenix, Arizona
35 mm slide presentation, Ritz-Carlton Hotel

Reducing the incidence of breast cancer with nolvadex in women at high risk 02/16/1999
Nico's Catacombs
35 mm slide presentation sponsored by Zeneca Pharmaceuticals

Regional

Cancer epidemiology, etiology & pathology 09/29/1980
Oncology seminar to nurses, McKennan Hospital

Cancer chemotherapy 10/02/1980
Sioux Valley Hospital Nurses at the Education Center

Diagnosis and screening tests for lung, breast and colon cancer 11/04/1980
Family Practice Residents Weekly Seminar
Sioux Falls, South Dakota

Hyperalimentation and cancer 12/11/1980
Oncology Seminar, McKennan Hospital Nurses

Central nervous system complications of cancer 12/12/1980
Staff Meeting, Brookings Hospital
Brookings, South Dakota

Cancer pain management 12/16/1980
Oncology Seminar, McKennan Hospital Nurses

Drug-curable cancer and cancer screening tests 12/17/1980
CPC Noon Seminar

Management of advanced prostatic adenocarcinoma 12/23/1980
McKennan Hospital Tumor Conference

Melanoma and breast cancer 03/12/1981
McKennan Hospital Oncology Seminar
Case presentations with discussion by Drs. Marschke and David Ahmann

Major cancer diagnoses and complications 03/24/1981
Sioux Valley Hospital Education Center
nurses and medical staff

Multiple myeloma, management of hypercalcemia 04/28/1981
Sioux Falls Tumor Conference
case presentations and discussions

Cancer pain management 06/09/1981
St. Joseph Hospital
Mitchell, South Dakota
nursing staff and medical staff meeting

Breast cancer screening and mammography 07/15/1981

CPC Noon Conference	
I can cope	08/17/1981
McKenna Hospital discussion of human anatomy and physiology as related to cancer spread, forms of cancer treatment and side effects of cancer treatments	
Breast cancer screening, diagnosis and management	08/19/1981
Family Practice Center residents meeting	
Information discussion regarding research study design as well as possible appropriate local clinical pilots and trials	08/26/1981
McKenna Hospital presentation for staff physicians, interns, family practice residents and internal medicine residents	
Recognition of cancer complications	09/09/1981
McKenna Hospital oncology nursing in-service conference	
Cancer chemotherapy	09/09/1981
McKenna Hospital Watertown, South Dakota nurses' in-service teaching conference	
Chemotherapy and cancer pain management	10/28/1981
Regional Medical Center Huron, South Dakota nurses in-service teaching conference	
Management of advanced breast cancer and adjuvant therapy	12/04/1981
Hospital Medical Staff Conference Brookings, South Dakota	
Medical oncology emergencies	01/13/1982
Family Practice Residents Sioux Falls, South Dakota	
Organization, moderation and discussion of four cases	01/16/1982
McKenna Hospital Tumor Board Conference	
Principles of cancer chemotherapy	01/18/1982
Sioux Valley Hospital Medical student lecture	
Practical chemotherapy	02/03/1982
McKenna Hospital Sioux Falls, South Dakota In-service nurses teaching program	
Cancer pain management	02/16/1982
VA Hospital Sioux Falls, South Dakota one hour seminar for medical staff and residents	
Management of advanced breast cancer and breast cancer adjuvant chemotherapy	02/17/1982
Minnesota Association of Family Practitioners, Southwest Region Slayton, Minnesota	
I can cope	02/22/1982
McKenna Hospital Sioux Falls, South Dakota discussion of history of cancer and cancer treatment, general principles of cancer	

metastases, complications, etc.	
Cancer pain management Dickinson County Hospital In-service Conference Spirit Lake, Iowa one hour	03/02/1982
Cancer pain management Nursing In-service Teaching Conference, McKenna Hospital	03/08/1982
Side-effects of therapy and behavioral changes among cancer patients Ministry for Cancer Patients Meeting, McKennan Hospital for local ministers and pastoral care representatives	03/11/1982
Colon cancer VA Hospital Sioux Falls, South Dakota one hour seminar for medical staff and residents	04/20/1982
Introduction to clinical oncology and clinical cancer research Family Practice Center Sioux Falls, South Dakota family practice residents - one hour	04/26/1982
Breast cancer adjuvant therapy and the current role of hormone receptor South Dakota State Medical Society Meeting Rapid City, South Dakota 40-minute presentation	05/21/1982
Cell kinetics and chemotherapy principles USD medical students at Sioux Valley Hospital one hour lecture	05/26/1982
Lung cancer after surgery Sioux Valley Hospital one hour - house staffs of McKenna Hospital and Sioux Valley Hospital	06/08/1982
Part I hypercalcemia, part II malignant pleural effusions managed by chest tube chemotherapy or sclerosing pleurodesis McKenna Hospital Nursing In-service Oncology Lecture Sioux Falls, South Dakota	06/22/1982
Medical oncology emergencies VA Hospital Sioux Falls, South Dakota one hour seminar for medical staff and residents	06/22/1982
Cancer pain management Methodist Hospital Mitchell, South Dakota nursing staff	07/14/1982
Central nervous system metastases and myelosuppressive complications Methodist Hospital Mitchell, South Dakota medical staff	07/14/1982
Cancer chemotherapy and cellular kinetics Sioux Valley Hospital one hour lecture to medical students	07/20/1982
Management of advanced Hodgkin's disease and cryptococcal meningitis McKenna Hospital Nursing In-service one hour	07/21/1982

Cancer chemotherapy McKenna Hospital Nursing In-service one hour	10/13/1982
Presentation of case of multiple myeloma Sioux Valley Hospital Tumor Board Conference one hour presentation and acted as conference moderator	10/19/1982
Medical oncology emergencies McKenna Hospital Nursing In-service Education one hour presentation	12/15/1982
Chemotherapy and cellular kinetics Sioux Valley Hospital one hour lecture to medical students	02/11/1983
I can cope McKenna Hospital an oncologist discusses cancer and its treatment - one hour	02/28/1983
Cigarette smoking and its medical implications by an oncologist Sioux Valley Hospital Wellness Center one hour	04/11/1983
Breast cancer and lung cancer Siouxland Chapter of American Association of Critical Care Nurses two hour lecture regarding the subject of breast cancer and a one hour lecture regarding the subject of lung cancer	04/28/1983
Adjuvant cancer therapy McKenna and Sioux Valley Hospital's house staff one hour lecture	05/03/1983
Non-Hodgkin's lymphoma and cancer pain management Tumor Board Conference at St. Mary's Hospital Pierre, South Dakota two 1-hour lectures to the medical and nursing staff	05/17/1983
St. Joseph's Hospital Mitchell, South Dakota Tumor Board Conference	06/13/1983
Cancer pain management Gregory, South Dakota 1-hour presentation	06/30/1983
The patient and family regarding the cancer diagnosis Gregory, South Dakota 1-hour presentation	06/30/1983
Central nervous system metastases Methodist Hospital Mitchell, South Dakota medical and nursing staff	07/14/1983
Myelosuppressive complications of chemotherapy Methodist Hospital Mitchell, South Dakota medical and nursing staff	07/14/1983
Marijuana as an antiemetic for cancer patients South Dakota state legislative hearing South Dakota 30-minute presentation and discussion @ Howard Johnson Hotel	08/08/1983

Introduction to clinical oncology and chemotherapy Family Practice Center, resident teaching conference 60-minute presentation	08/29/1983
Cancer: prevention, screening and newer treatment methodology First Lutheran Church Sioux Falls, South Dakota 60 minute presentation arranged by Mrs. Karyn Pedersen, approximately 80 parishioners were present	09/1983
Methodist Hospital Mitchell, South Dakota Tumor Board Conference	09/12/1983
Cancer pain management Methodist Hospital Mitchell, South Dakota 90-minute presentation as an In-service to nurses	09/12/1983
Evaluation and management of nausea and vomiting in the cancer patient Methodist Hospital Mitchell, South Dakota 90-minute presentation as an In-service to nurses	09/12/1983
Cancer pain management USD Informational Exchange 60 minutes	09/14/1983
Nausea and vomiting in the patient with cancer, antiemetic management Divine Providence Hospital Ivanhoe, Minnesota medical staff meeting, 45 minutes	09/15/1983
Immunosuppression: the cancer patient McKenna Hospital 60-minute presentation, critical care in-service nursing education program	10/05/1983
Lung cancer screening: is early diagnosis worthwhile? Part I, and Evaluation of the patient with suspected lung cancer, Part II Central Plains Clinic noon luncheon 60 minute presentation, 1 hour CME	10/19/1983
Common laboratory tests on importance vis-a-vis the cancer patient Sioux Valley Hospital nursing in-service presentation, 60 minutes	10/19/1983
Discussion of cancer cases St. Ann's Hospital Watertown, South Dakota Tumor Board Conference, 60 minute discussion	10/24/1983
Chemotherapy of malignant neoplasms Dept of Biochemistry, USD School of Medicine Vermillion, South Dakota 2-hour lecture to freshman medical students	11/09/1983
Cancer chemotherapy and cellular kinetics Sioux Valley Hospital Department of Obstetrics and Gynecology Core clerkship lecture series for junior medical students, 75 minutes	01/11/1984
Breast cancer Family Practice Center presentation to family practice residency program, 75 minutes	01/17/1984

St. Joseph's Hospital Mitchell, South Dakota Tumor Board Conference - moderator for one hour	02/13/1984
Cancer prevention, detection and treatment in 1984 Altrusa Club, Downtown Holiday Inn 60 minutes	02/23/1984
Cancer prevention, detection and treatment in 1984 Rotary Club, downtown Holiday Inn 45 minutes	02/27/1984
Case presentations of periampullary adenocarcinoma and carcinoid tumor of small bowel Brookings Hospital Tumor Board Conference - 60 minutes	03/02/1984
Nutrition and cancer McKenna Hospital nurses conference from 2 p.m. to 3 p.m.	03/07/1984
Breast cancer: an overview Black Hills Medical Center medical and nursing staff, 60-minute presentation	03/10/1984
Non-small cell lung cancer screening and the current management of small cell lung cancer Black Hills Medical Center medical and nursing staff, 60-minute presentation	03/10/1984
Sioux Valley Hospital Wellness Center Tumor Board Conference, 5-6 p.m.	03/20/1984
Management of pain and management of nausea and vomiting in the cancer patient Family Practice Center 60-minutes, group of approximately 30 staff physicians and family practice residents	04/11/1984
Cancer chemotherapy and cellular kinetics Sioux Valley Hospital 60-minute lecture to junior medical students rotating through Obstetrics/Gynecology	05/16/1984
Breast cancer cases, mammographic findings, pathologic findings and discussion of breast cancer staging and management Tumor Board Clinic, Brookings Hospital 60 minutes	06/01/1984
Infections, myelosuppression and immune deficiency in the cancer patient Marshall Hospital Marshall, Minnesota 60-minute presentation to medical staff	06/27/1984
Death and dying Family Practice Center, Inc. 60-minute presentation to residents and staff	08/15/1984
Common cancer screening recommendations Family Practice Center 60-minute presentation to staff and residents	08/27/1984
Rectal cancer Brookings Hospital	09/07/1984

Brookings, South Dakota Tumor Board Conference, 60-minutes	
Detection and management of breast cancer Holiday Inn Downtown conference co-sponsored by the American Cancer Society and South Dakota State University; 45-minute discussion of breast cancer detection including the role of mammography and tumor markers; also presented a 20-minute discussion on the role of chemotherapy in management of breast cancer	09/27/1984
A discussion of cancer from an oncologist's viewpoint Hospice Volunteer Training Program	10/08/1984
St. Anne's Hospital Watertown, South Dakota Tumor Board Conference (60 minutes)	10/22/1984
Moderation of 3 cases, including gallbladder carcinoma, metastatic colonic adenocarcinoma and metastatic breast carcinoma Sioux Valley Hospital Tumor Board and Pathology Conference 60 minutes, noon meeting	11/08/1984
Hodgkin's disease and non-Hodgkin's lymphoma Brookings Hospital Tumor Board Conference, a joint seminar with Dr. Jeffrey Hagen, 60 minutes	12/14/1984
Chemotherapy and cell kinetics McKenna Hospital Obstetrics and Gynecology Rotation a lecture to junior medical students, 60 minutes	01/16/1985
Cancer, cause-prevention-early detection-and-treatment in 1985 O'Gorman High School 40 minute presentation given twice to junior and senior high school students (men and women)	02/02/1985
Cancer and its treatment, the perspective of a medical oncologist McKenna Hospital I Can Cope meeting, 90-minute presentation to patients, families and nursing staff	02/18/1985
Presenting 4 cases of endometrial adenocarcinoma Brookings Hospital Tumor Board Conference Brookings, South Dakota attended by Dr. Jeffrey Hagen and members of Brookings Hospital staff, 60 minutes	03/01/1985
Management of primary and recurrent breast cancer Veteran's Administration Hospital 60-minute conference presented to internal medicine residents, medical students and medical staff	03/19/1985
Emergencies in medical oncology USD School of Medicine 60-minute presentation teleconference exchange, 12:30 - 1:30 pm followed by a question and answer session	04/03/1985
Emergencies in medical oncology Family Practice Center Sioux Falls, South Dakota 60-minute presentation to family practice residents, noon conference, 12:15 - 1:15 p.m.	04/10/1985
Medical oncology emergencies McKenna Hospital Annual Oncology Hematology Symposium 25-minute presentation	05/03/1985

Chemotherapy and cellular kinetics McKenna Hospital lecture to junior medical students on OB-GYN rotation, 12:15 - 1:30 p.m.	05/08/1985
Methotrexate, biochemistry and rationale of high-dose therapy with citrovorum factor rescue Sioux Valley Hospital 60 minutes, nursing in-service conference	05/08/1985
Ovarian carcinoma Brookings Hospital Tumor Board Conference 60-minute presentation	06/14/1985
Cancer chemotherapy and cellular kinetics 60-minute lecture to junior medical students on gynecology	06/25/1985
Cancer etiology, early detection, etc. KSOO Radio Medical Line 45 minutes on radio medical line with Dr. Jerry Walton	07/11/1985
Medical oncology emergencies St. Mary's Hospital Pierre, South Dakota 60 minutes, medical staff meeting	07/16/1985
Medical oncology emergencies Veterans Administration Hospital noon conference for interns, residents and medical students, 60 minutes	08/20/1985
Methodist Hospital Mitchell, South Dakota Tumor Board Conference from 12:00 - 1:00 p.m.	10/14/1985
Cancer chemotherapy - clinical correlation SD School of Medicine, Dept. of Biochemistry Vermillion, South Dakota 90-minute lecture to freshman medical students	10/28/1985
Mammography 1985 McKenna Hospital Physician Educational Symposium presented at Downtown Holiday Inn	11/15/1985
Lung cancer staging, staging tests, and non-surgical management Brookings Hospital Tumor Board Conference, 60 minutes	12/13/1985
Breast cancer, early recognition of primary tumor and recurrence Family Practice Center Family Practice Residency Program, 60 minutes	01/08/1986
Management of the patient with febrile neutropenia Merck, Sharp and Dohme Regional Representatives 90 minutes	01/09/1986
Cancer screening Veterans Administration Hospital resident and student lecture, 60 minutes	02/18/1986
Metastatic bone cancer and Management of the cancer patient with bone metastases Sioux Valley Hospital local chapter of National Association of Orthopedic Nurses, (20 R.N.'s in attendance), 60 minutes	02/25/1986

Immune deficiency among the aged and among patients with cancer Sioux Falls Rural Area Health Education Center 60 minute presentation to 41 registered nurses	06/12/1986
Principles of chemotherapy and cellular kinetics lecture to junior medical students in obstetrics and gynecology rotation, 60 minutes	07/11/1986
Discussion of primary breast cancer management, the role of segmental mastectomy plus axillary dissection followed by radiontherapy Yankton Sacred Heart Hospital Tumor Board Conference 60 minutes	07/12/1986
Discussion of several cases Methodist Hospital Mitchell, South Dakota Tumor Board Conference, 60 minutes	08/11/1986
Malignant neoplasm of unknown origin Brookings Hospital Tumor Board Conference, 60 minutes	09/12/1986
Cancer pain management VA Internal Medicine Noon Conference 60 minutes	09/16/1986
Care of immunosuppressed patient McKenna Hospital Annual Oncology Hematology Symposium 30 minutes	09/26/1986
Diet and cancer and Early cancer detection and cancer prevention Public Education Symposium Gilbert Science Center Alumni Auditorium, Augustana College, co-sponsored by the Sioux Falls Community Cancer Consortium and the American Cancer Society, 30 minute presentation	10/04/1986
Cancer chemotherapy, a clinical correlation lecture USD School of Medicine Vermillion, South Dakota 60 minutes, for biochemistry medical students	10/30/1986
Common cancer screening recommendations Family Practice Center 60 minutes, 30 physicians present	11/04/1986
Chemotherapy and cell kinetics McKenna Hospital 1 hour lecture to medical students	01/21/1987
Medical oncology emergencies McKenna Hospital 60 minute presentation to the nursing staff	04/08/1987
Chemotherapy and cell kinetics McKenna Hospital 60 minute presentation to medical students	04/22/1987
Presentation of a case of resected stage III non-small cell lung cancer Scottsdale Memorial Hospital - Osborne Scottsdale, Arizona Tumor Conference, 60 minutes	07/24/1987
Presentation of a case of resected stage III non-small cell lung cancer Scottsdale Memorial Hospital - Osborne	09/28/1987

Scottsdale, Arizona Tumor Conference, 60 minutes	
Cancer medical therapy Scottsdale Memorial Hospital - Osborn Scottsdale, Arizona one hour presentation for registered nurse chemotherapy recertification	12/07/1987
Management of the myelosuppressed patient Scottsdale Memorial Hospital - North Scottsdale, Arizona two hourly conferences presented to the nursing staff	03/02/1988
Mayo Clinic Scottsdale and Cancer prevention and early detection Scottsdale Sunrise Rotary Club Scottsdale, Arizona	03/03/1988
Adjuvant cancer therapy, current perspectives in oncology Arizona State Medical Association Meeting Phoenix, Arizona	03/05/1988
Death, the dying patient, and the patient's family Scottsdale Memorial Hospital - North Scottsdale, Arizona physician assistant lecture series	03/07/1988
Nausea and vomiting in the cancer patient Scottsdale Memorial Hospital North Scottsdale, Arizona 60 minute presentation to staff nurses	06/01/1988
Carcinoid tumor Ashton B. Taylor Auditorium, Mayo Clinic Scottsdale Scottsdale, Arizona presentation of a case and literature review, medical staff lecture	09/09/1988
Chemotherapy and cell kinetics Scottsdale Memorial Hospital - Osborn Scottsdale, Arizona presented to Scottsdale Memorial Health Care Systems nursing staff	09/09/1988
The clinical utility of common malignancy markers Mayo Clinic Scottsdale Clinical Reviews Scottsdale, Arizona	04/03/1989
Mayo Comprehensive Cancer Center Urologic Oncology Teleconference Scottsdale, Arizona teleconference presented in the Ashton B. Taylor Auditorium in cooperation with Mayo Clinic Rochester and Mayo Clinic Jacksonville	06/10/1989
Breast cancer update Mayo Clinic Scottsdale Scottsdale, Arizona 60 minute presentation to the registered nursing and paramedical staff	07/20/1989
Breast cancer update Scottsdale Memorial Hospital - North Scottsdale, Arizona 60 minute presentation to the registered nursing and paramedical staff	07/20/1989
Cancer control session I Hematology and Oncology Review Course for the Primary Care Physician Scottsdale, Arizona Orange Tree Golf Resort	10/05/1990

Adjuvant therapy for common malignancies Arizona Geriatrics Society Annual Meeting Mesa, Arizona Arizona Golf and Conference Center	03/03/1991
Oncologic complications and the future of oncology Scottsdale Memorial Hospital Chemotherapy Oncology Nursing Course Scottsdale, Arizona	03/28/1991
When should cancer NOT be treated Mayo Clinic Scottsdale Clinical Reviews Scottsdale, Arizona Meet the Preceptor Luncheon	04/25/1991 - 04/26/1991
New developments in breast cancer and colorectal cancer adjuvant therapy Arizona Geriatrics Society Meeting Mesa, Arizona Arizona Golf Resort and Conference Center	10/25/1991
Breast cancer Scottsdale Memorial Hospital - North Scottsdale, Arizona presentation to registered nurses as a part of the Advanced Oncology Series	10/31/1991
Management of disseminated prostate cancer and Ovarian cancer: systemic therapy Mayo Clinic Scottsdale Hematology/Oncology Course Scottsdale, Arizona Orange Tree Resort	11/01/1991
Does everything cause cancer Kiwanis Club of Fountain Hills Fountain Hills, Arizona	06/25/1992
Management of node negative breast cancer Scottsdale Memorial Hospital - North Scottsdale, Arizona Tumor Board Conference	10/12/1992
Approach to unknown primary cancers Hematology and Oncology Course	10/30/1992
Adjuvant tamoxifen for node negative breast cancer Scottsdale Memorial Hospital - North Scottsdale, Arizona Medical/Surgical Conference	11/19/1992
Patient with metastatic colon cancer Medical Surgical Conference case presentation	01/21/1993
Care of the terminally ill cancer patient Scottsdale Memorial Hospital - North Scottsdale, Arizona resident conference presentation	02/11/1993
Breast cancer etiology and prevention Scottsdale Memorial Hospital - North Scottsdale, Arizona presentation to registered nurses	09/1993
Advances in oncology Hematology and Oncology for Primary Care Physicians	10/30/1993

Scottsdale, Arizona	
Breast cancer detection and treatment Community Cancer Awareness Program, Mayo Clinic Scottsdale Phoenix, Arizona presented at the Hyatt Regency Hotel	06/25/1994
State of the art treatment of small-cell lung cancer Maricopa Medical Center	07/07/1995
Analgesics for cancer patient pain Scottsdale Memorial Hospital - North 60 minute presentation for the residents, tumor registrars, medical staff and paramedical professional support staff	08/29/1995
Prostate cancer prevention trial Arizona African/American Broadcasting, Inc. Phoenix, Arizona radio talk show	10/08/1995
When should cancer not be treated? Scottsdale Memorial Hospital - North Scottsdale, Arizona 60 minute presentation for the residents, tumor registrars, medical staff and paramedical professional support staff	01/15/1996
Management of cancer of unknown primary source Scottsdale memorial Hospital - North Scottsdale, Arizona 60 minute presentation for the residents, tumor registrars, medical staff and paramedical professional support staff	02/05/1996
New developments in the systemic therapy of prostate cancer Scottsdale Memorial Hospital - North Urology Conference Scottsdale, Arizona 60 minutes	05/21/1996
Prostate cancer prevention trial Maricopa Medical Center Phoenix, Arizona National Hispanic Nurses Association, Phoenix Chapter	06/20/1996
Prostate cancer screening: what age? what tests? and Febrile neutropenia: an emergency for hematology-oncology patients Medical Staff Dinner Meeting Sidney, Nebraska	09/25/1996
When should cancer not be treated Mayo Clinic Scottsdale Clinical Reviews Phoenix, Arizona 35 mm slide presentation, Ritz-Carlton Hotel	11/22/1996
Breast cancer risk and prevention, the breast cancer prevention trial Poudre Valley Hospital 35 mm slide presentation to the public	04/29/1997
Diet, vitamins, nutrition and cancer Poudre Valley Hospital 35 mm slide presentation to Aspen Club Dinner (retired persons club)	05/02/1997
Communications with the dying cancer patient and the patient's family Poudre Valley Hospital 35 mm slide presentation to the oncology registered nursing staff	06/09/1997

Diet, vitamins, nutrition and cancer Poudre Valley Hospital Staff Fort Collins, Colorado 35 mm slide presentation	06/10/1997
New developments in cancer therapy: monoclonal antibody treatments Volunteer Appreciation Day for the American Cancer Society at the Harmony Presbyterian Church Fort Collins, Colorado 35 mm slide presentation	09/12/2000
Hereditary colorectal cancer and colorectal cancer early detection Oncology Nursing Society Meeting Windsor, Colorado 35 mm slide presentation, Ptarmigan Country Club	09/26/2001

RESEARCH INTERESTS

1. North Central Cancer Treatment Group, Sioux Falls Center, 1981-1987, Principal Investigator.
2. North Central Cancer Treatment Group, National Cancer Institute Community Clinic Oncology Program Grant Awards, 1983-1987, Principal Investigator.
3. North Central Cancer Treatment Group, Mayo Clinic Scottsdale, 1987-1996, Principal Investigator.
4. North Central Cancer Treatment Group, National Cancer Institute Community Clinical Oncology Program Grant Awards, Scottsdale CCOP, 1993-1996 (funded through 2001), Principal Investigator.
5. Mayo Phase II Contract Grant Award, National Cancer Institute, 1990-1992, Co-Investigator.
6. Scientific Coordinator, NCCTG, Lung Oncology Program, 1994-1996.

RESEARCH GRANTS AWARDED

Active Grants

Federal

Co-Investigator	The North Central Cancer Treatment Group. Funded by National Cancer Institute. (CA 25224)	03/1994 - 12/2006
-----------------	---	-------------------

Industry

Principal Investigator	(C3-05-001) ...and Pharmacokinetic Study of...CX-3543, ...in Patients with Advanced Solid Tumors or Lymphomas. Funded by Cylene Pharmaceuticals, Inc.	07/2005 - 06/2006
Principal Investigator	(C3-05-001)...and Pharmacokinetic Study of CX-3543, in Patients with Advanced Solid Tumors or Lymphomas. Funded by Cylene Pharmaceuticals, Inc.	07/2005 - 06/2006

Completed Grants

Federal

Principal Investigator	Scottsdale Community Clinical Oncology Program. Funded by National Cancer Institute. (CA 60276)	09/1993 - 05/1997
------------------------	---	-------------------

Industry

Principal	A Comparison Of Two Doses Of Letrozole Versus Megestrol	06/1994 - 06/1997
-----------	---	-------------------

Investigator	Acetate In Postmenopausal Women With Advanced Breast Cancer. Funded by Ciba Geigy. (Cibageigy #47S)	
Co-Investigator	A dose-Ranging, Efficacy, Safety and Pharmacokinetic Study of single Intravenous Doses of RS-25259 for Prevention of nausea or Vomiting in Chemotherapy-Naive Cancer Patients Receiving Highly Emetogenic Chemotherapy. Funded by Syntex USA, Inc. (Syntex #95)	05/1994 - 04/1995

BIBLIOGRAPHY

Peer-reviewed Articles

1. Parish JM, Marschke RF Jr, Dines DE, Lee RE. Etiologic considerations in superior vena cava syndrome. *Mayo Clin Proc* 1981 Jul; 56(7):407-13.
2. Windschitl H, Scott M, Schutt A, McCormack G, Everson L, Cullinan S, Gerstner J, Krook J, Laurie J, Shreck R, Laurie J, Shreck R, Marschke R, Pfeifle D. Randomized phase II studies in advanced colorectal carcinoma: a North Central Cancer Treatment Group study. *Cancer Treat Rep* 1983 Nov; 67(11):1001-8.
3. Creagan ET, Green SJ, Ahmann DL, Ingle JN, Edmonson JH, Marschke RF Jr. A phase III clinical trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5-fluorouracil, prednisone in patients with advanced breast cancer. *J Clin Oncol* 1984 Nov; 2(11):1260-5.
4. Ingle JN, Green SJ, Brunk SF, Krook JE, Everson LK, Cullinan SA, Pfeifle DM, Kvols LK, Reuter NF, Laurie JA, Marschke RF Jr, Ahmann DL. Randomized clinical trial of doxorubicin alone or combined with mitolactol in women with advanced breast cancer and prior chemotherapy. *Am J Clin Oncol* 1985; 8:275-282.
5. Krook JE, Ingle JN, Green SJ, Bowman WD, Everson LK, Windschitl HE, Marschke RF Jr, Laurie JA, Cullinan SA, Pfeifle DM, McCormack GW, Elliot TE. Randomized clinical trial of cyclophosphamide, 5-fluorouracil, prednisone with or without tamoxifen in postmenopausal women with advanced breast cancer. *Cancer Treat Rep* 1985; 69:355-361.
6. Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, Windschitl HE, Twito DI, Marschke RF, Foley JF. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. *JAMA* 1985 Apr 12; 253(14):2061-7.
7. Krook JE, Jett JR, Fleming TR, Dalton RJ, Marschke RF Jr, Cullinan SA, Windschitl HE, Everson LK, Brunk FS, Laurie JA, Foley JF, Larson D. A controlled evaluation of combined 5-FU, doxorubicin, and Mitomycin C (FAM) for the treatment of advanced non-small cell lung cancer for the North Central Cancer Treatment Group. *Journal of Clinical Oncology* 1985 Jun; 3(6).
8. Buroker TR, Moertel CG, Fleming TR, Everson LK, Cullinan SA, Krook JE, Mailliard JA, Marschke RF, Klaassen DJ, Laurie JA. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma. *J Clin Oncol* 1985 Dec; 3(12):1624-31.
9. Marschke RF Jr, Kvols LK, Cullinan SA, Laurie JA, Mailliard JA, Tschetter LK, O'Connell MJ. Phase II study of bisantrene administered by continuous 72-hour infusion for advanced pancreatic adenocarcinoma. *Medical & Pediatric Oncology* 1988; 16(4):269-70.
10. Ingle JN, Twito DI, Schaid DJ, Cullinan SA, Krook JE, Mailliard JA, Marschke RF, Long HJ, Gerstner JG, Windschitl HE. Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer. *J Clin Oncol* 1988 May; 6(5):825-31.
11. Cascino TL, Brown LD, Morton RF, Everson LK, Marschke RF, Dinapoli RP, O'Fallon JR. Evaluation of fludarabine phosphate in patients with recurrent glioma. *Am J Clin Oncol* 1988 Oct; 11(5):586-8.
12. Marschke RF, Ingle JN, Schaid DJ, Krook JE, Mailliard JA, Cullinan SA, Pfeifle DM, Votava HJ, Ebbert LP, Windschitl HE. Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancer. *Cancer* 1989 May 15; 63(10):1931-7.

13. Ingle JN, Mailliard JA, Schaid DJ, Krook JE, Gerstner JB, Pfeifle DM, Marschke RF, Long HJ, McCormack GW, Foley JF. Randomized trial of doxorubicin alone or combined with vincristine and mitomycin C in women with metastatic breast cancer. *Am J Clin Oncol* 1989 Dec; 12(6):474-80.
14. Jett JR, Everson L, Therneau TM, Krook JE, Dalton RJ, Marschke RF, Veeder MH, Brunk SF, Mailliard JA, Twito DI. Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group. *J Clin Oncol* 1990 Jan; 8(1):33-8.
15. Hartmann LC, Marschke RF, Schaid DJ, Ingle JN. Systemic adjuvant therapy in women with resected node-negative breast cancer. *Mayo Clin Proc* 1991 Aug; 66(8):805-13.
16. Veeder MH, Jett JR, Su JQ, Mailliard JA, Foley JF, Dalton RJ, Etzell PS, Marschke RF, Kardinal CG, Maksymiuk AW, Ebbert LP, Tazelaar HD, Wittrak GA. A phase III trial of mitomycin C alone versus mitomycin C, Vinblastine, and cisplatin for metastatic squamous cell lung carcinoma. *Cancer* 1992 Nov; 70(9):2281-7.
17. Goldberg RM, Krook J, Maksymiuk AW, Marschke RF Jr. Treatment of non-small cell lung Cancer with short term infusion of cisplatin and etoposide: a review of the literature. *J Infus Chemother* 1994; 4(4):151-4.
18. Martenson JA Jr, Schutt AJ, Grado GL, Maples WJ, Marschke RF Jr. Prospective phase I evaluation of radiation therapy, 5-fluorouracil, and levamisole in locally advanced gastrointestinal cancer. *Int J Radiat Oncol Biol Phys* 1994 Jan 15; 28(2):439-43.
19. Witzig TE, Letendre L, Gerstner J, Schroeder G, Mailliard JA, Colon-Otero G, Marschke RF, Windschitl HE. Evaluation of a somatostatin analog in the treatment of lymphoproliferative disorders: results of a phase II North Central Cancer Treatment Group trial. *J Clin Oncol* 1995 Aug; 13(8):2012-5.
20. Schleusener JT, Tazelaar HD, Jung SH, Cha SS, Cera PJ, Myers JL, Creagan ET, Goldberg RM, Marschke RF. Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma. *Cancer* 1996 Apr 1; 77(7):1284-91.
21. Ingle JN, Twito DI, Suman VJ, Krook JE, Mailliard JA, Windschitl HE, Marschke RF. Evaluation of intravenous 6-thioguanine as first-line chemotherapy in women with metastatic breast cancer. *Am J Clin Oncol* 1997 Feb; 20(1):69-72.
22. Colon-Otero G, Marschke R, Camoriano JK, Sorensen JM, Sloan JA, Richardson RL. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas. *Cancer J Sci Am* 1997 Sep-Oct; 3(5):297-302.
23. Creagan ET, Rowland KM Jr, Suman VJ, Kardinal CG, Marschke RF Jr, Marks RS, Maples WJ. Phase II study of combined levamisole with recombinant interleukin-2 in patients with advanced malignant melanoma. *Am J Clin Oncol* 1997 Oct; 20(5):490-2.
24. Bonner JA, McGinnis WL, Stella PJ, Marschke RF, Sloan JA, Shaw EG, Mailliard JA, Creagan ET, Ahuja RK, Johnson PA. The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III Study. *Cancer* 1998 Mar 15; 82(6):1037-48.
25. Creagan ET, Hestorff RD, Suman VJ, Mailliard JA, Nair S, Krook JE, Kugler JW, Marschke RF Jr, Michalak JC, Tschetter LK. Combined levamisole with recombinant interleukin-2 (IL-2) in patients with advanced renal cell carcinoma: a phase II study. *Am J Clin Oncol* 1998 Apr; 21(2):139-41.

26. Maksymiuk AW, Marschke RF Jr, Tazelaar HD, Grill J, Nair S, Marks RS, Brooks BJ, Mailliard JA, Burton GM, Jett JR. Phase II trial of topotecan for the treatment of mesothelioma. *Am J Clin Oncol* 1998 Dec; 21(6):610-3.
27. Marschke RF Jr, Grill JP, Sloan JA, Wender DB, Levitt R, Mailliard JA, Gerstner JB, Ghosh C, Morton RF, Jett JR. Phase II study of high-dose somatostatin analogue in patients either previously treated or untreated who have extensive-stage small cell lung cancer. *Am J Clin Oncol* 1999 Feb; 22(1):15-7.
28. Weitz JJ, Marschke RF Jr, Sloan JA, Grill JP, Jett JR, Knost JA, Hatfield AK, Zenk DW, Bate WW, Schaefer PL. A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer. *Lung Cancer* 2000 May; 28(2):157-62.

Abstracts and Letters

1. van Hazel GA, Marschke RF Jr, Martin JK, Greene SJ Jr, Bisel HF. Male breast cancer (MBC) Mayo Clinic experience. 4th Annual San Antonio Breast Cancer Symposium 1981 Nov.
2. Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, Windschitl HE, Twito DL, Marschke RF, Foley JF, Pfeifle DM, Barlow JF. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin and mitomycin. *Year Book of Drug Therapy* 1986; Article 11-23.
3. Marschke RF, Jett J, Everson L, O'Fallon J, Cullinan S, Krook J, Earle J. Randomized trial of CAV with or without VP-16 for limited disease small cell lung cancer: a North Central Cancer Treatment Group Study (Abstract 669). *Proceedings of ASCO* 1986; 5:171.
4. Elliot T, Dinapoli R, O'Fallon J, Roers B, Earle J, Morton R, Etzel P, Marschke RF, Scheithauer B. Randomized trial of radiation therapy plus dibromodulcitol versus radiation therapy plus BCNU in high grade astrocytoma: a North Central Treatment Group Study (Abstract 505). *Proceedings of ASCO* 1986 Mar; 5:130.
5. Marschke RF, Kvols L, Cullinan S, Laurie J, Mailliard J. A phase II trial of bisantrene administered by 72 hour infusion for advanced measurable pancreatic carcinoma: a North Central Cancer Treatment Group and Mayo Clinic Study (Abstract 720). *Proceedings of the American Association for Cancer Research* 1986 Mar; 27:182.
6. Twito DI, Ingle JN, Chang MN, Cullinan SA, Krook JE, Mailliard JA, Marschke RF, Long HJ. Randomized trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer: a collaborative trial for the North Central Cancer Treatment Group and Mayo Clinic (Abstract 242). *Proceedings of ASCO* 1986 Mar; 5:62.
7. Marschke RF, Dines DE. Sarcoidosis and malignant neoplasm: The Mayo Clinic experience; Sarcoidosis: International review of sarcoidosis and other granulomatous disorders. 1986 Sept; 3(2):149-150.
8. Marschke RF Jr, Ingle JN, Schaid DJ, Krook JE, Cullinan SA, Pfeifle DM. Randomized trial of cyclophosphamide, methotrexate, 5-fluorouracil, prednisone (cmfp) versus cfp in women with metastatic breast cancer. (Abstract no. 40). *Proc Am Soc Clin Oncol* 1988 Mar; 7:11.
9. Frytak S, Shaw EG, Eagan R, Creagan ET, Richardson RL, Jett J, Foote RL, Colon-Otero G, Buskirk SJ, Marschke RF Jr, Fitch TR, Grado GL, Therneau TM. Accelerated hyperfractionated split-course thoracic radiotherapy (AHSCRT) and infusion cisplatin based chemotherapy (CT) for small lung cancer (SCLC) (Abstract 906). *Proc Annu Meet Am Soc Clin Oncol* 1990; 9:234.

10. Frytak S, Shaw EG, Eagan R, Creagan ET, Richardson RL, Jett J, Foote RL, Colon-Otero G, Buskirk SJ, Marschke RF Jr, Fitch TR, Grado GL, Su J. Accelerated hyperfractionated split-course thoracic radiotherapy (AHSCTRT) and infusion cisplatin based chemotherapy (CT) for small cell lung cancer (SCLC). (Abstract 899). Proc Annu Meet Am Soc Clin Oncol 1991; 10:260.
11. Frytak S, Shaw E, Eagan R, Creagan E, Richardson R, Jett J, Foote R, Colon-Otero G, Buskirk S, Marschke RF, Fitch T, Grado G, Su J. Accelerated hyperfractionated split-course thoracic radiotherapy (AHSCTRT) and infusion cisplatin based chemotherapy (CT) for small cell lung cancer (SCLC). Third Annual Pittsburgh Cancer Conference Pittsburgh, PA 1992 Nov:18.
12. Fitch R, Camoriano JK, Greene M, Braich TA, Marschke RF Jr, Colon-Otero G, Rubin J. Intravenous fazarabine (arabinsoyl-5- azacytosine, Ara-AC) for advanced non-small cell lung carcinoma (NSCLC). (Abstract no. 1200). Program/Proc Am Soc Clin Oncol 1993 Mar; 12:356.
13. Kochhar R, Frytak S, Shaw EG, Eagan RT, Creagan ET, Richardson RL, Jett JR, Foote RL, Colon-Otero G, Buskirk SJ, Marschke RF Jr, Fitch T, Grado GL, Su J. Accelerated hyperfractionated split-course thoracic radiotherapy (AHSCTRT) and infusion cisplatin based chemotherapy (CT) for limited-small cell lung cancer (SCLC). (Abstract no. 1111). Program/Proc Am Soc Clin Oncol 1993 Mar; 12:333.
14. Marschke RF Jr. Colorectal cancer adjuvant therapy. Hematology/Oncology Update: Current Issues and Controversies 1994; 1-11.
15. Marschke RF Jr. Management of cancer of unknown primary source. Hematology/Oncology Update: Current Issues and Controversies 1994; 1-7.
16. Marschke RF Jr. Percutaneous ethanol injection therapy for malignant hepatic neoplasms. Hematology/Oncology Update: Current Issues and Controversies 1994; 1-5.
17. Marschke RF Jr, Wieand HS, O'Connell MJ, Rubin J, Schutt AJ, Burch PA, Kovach JS. Advanced colorectal adenocarcinoma: treatment with amonafide. J Natl Cancer Inst 1994 Jun 15; 86(12):944-5.
18. Colon-Otero G, Solberg LA Jr, Wilson D, Marschke R, Fitch T, Camoriano J, Maples WJ, Hook CC, Cha SS, Wieand HS. A phase I trial of continuous intravenous infusion of interleukin-1 beta followed by carboplatin and cyclophosphamide in patients with advanced malignancies. American Society of Hematology Meeting 1994 Dec.
19. Wender DB, Grill J, Marschke RF Jr, Jett JR. Phase II trial of high dose somatostatin analogue (ssa), Sandostatin, in previously untreated patents with extensive stage small cell lung carcinoma: a North Central Cancer Treatment Group (NCCTG) trial. (Meeting abstract a1501). Proc Annu Meet Am Soc Clin Oncol 1995; 14:348.
20. Schleusener J, Tazelaar HD, Jung S, Cera P, Myers JL, Creagan ET, Goldberg RM, Marschke RF Jr. Neuroendocrine (ne) differentiation correlates with survival in chemotherapy treated non-small cell lung cancer (NSCLC). (Abstract no. 897). Mod Pathol 1995 Jan; 8:153A.
21. Schleusener J, Tazelaar HD, Jung S, Cera P, Myers JL, Creagan ET, Goldberg RM, Marschke RF Jr. Neuroendocrine (ne) differentiation correlates with survival in chemotherapy treated non-small cell lung cancer (NSCLC). (Abstract 897). Lab Invest 1995 Jan; 72:153A.
22. Colon-Otero G, Camoriano JK, Marschke RF Jr, Sorensen JM, Richardson RL. Edatrexate in combination with vinblastine, doxorubicin, cisplatin and Neupogen (EVAC/G-CSF) is an active regimen against non-small cell lung cancer and transitional cell carcinomas of the urothelium: preliminary results of a dose seeking trial. (Abstract 1180). Program/Proc Am Soc Clin Oncol 1995 Mar; 14:380.

23. Maksymiuk AW, Jung SH, Marschke RF Jr, Nair KS, Jett JR. Phase II trial of topotecan in pleural mesothelioma: a North Central Cancer Treatment Group (NCCTG) trial. (Abstract no. 1383). Program/Proc Am Soc Clin Oncol 1995 Mar; 14:435.
24. Marschke RF Jr, Schroeder G, Fitch TR, Pitot H, Rubin J. Phase II trial of combined 5-fluorouracil and levamisole in patients with advanced colorectal cancer. (Abstract no. 543). Program/Proc Am Soc Clin Oncol 1995 Mar; 14:216.
25. McGinnis WL, Shaw EG, Jung SH, Jett J, Stella P, Marschke RF Jr, Kugler J, Mailliard J, Wiesenfeld M, Frytak S, Poon M. Results of a phase III prospective randomized trial comparing standard thoracic radiation therapy (TRT) to twice-daily (bid) TRT +/- concomitant etoposide-cisplatin (EP) chemotherapy in patients with unresectable stage IIIA/b non-small cell lung cancer (NSCLC). (Abstract no. 1079). Program/Proc Am Soc Clin Oncol 1995 Mar; 14:355.
26. Weitz JJ, Jung SH, Marschke RF Jr, Fitch TR, Jett JR. Randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung carcinoma (NSCLC): a North Central Cancer Treatment Group (NCCTG) trial. (Abstract no. 1053). Program/Proc Am Soc Clin Oncol 1995 Mar; 14:348.
27. Pakanati AR, Marschke RF, Dennis LK. Cancer of unknown primary: a retrospective review of histopathology, chemotherapy and outcome. (Abstract no. 1415). Program/Proceedings American Society of Clinical Oncology 1996 Mar; 15:452.

Recent Publications

1. R. F. Marschke, A. D. Ricart, D. D. Von Hoff, J. K. Lim, K. Papadopoulos; Phase I clinical trial of CX-3543, a pro-apoptotic antitumor agent; *Journal of Clinical Oncology*, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 3082; **Background:** CX-3543 is a novel small molecule specifically designed to target three dimensional nucleic acid motifs, and thus induce apoptosis in cancer cells. Preclinically, CX-3543 demonstrated potency in suppressing xenograft tumor growth with a broad therapeutic window. The objectives of this phase I study are: to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs), to establish the pharmacokinetics (PKs), and to determine the recommended dose for further clinical development of CX-3543. **Methods:** Eligible patients with advanced solid tumors or lymphomas whose tumors progressed on standard therapy or for whom there are no standard therapies receive CX-3543 in successive dose cohorts at: 10, 20, 40, 80 and 160 mg/m². Dosing is by one hour intravenous infusion daily for five consecutive days repeated on a three week cycle. Therapy is continued until the patient shows signs of intolerance to CX-3543 or evidence of advancing disease. Response by RECIST criteria is determined after every 2 cycles. **Results:** Ten patients with solid tumors (3-4 per cohort) have received intravenous CX-3543. Doses have been well tolerated. Seven grade 3 adverse events have been reported during the study, but none of these are related to CX-3543. To date no objective responses have been observed. One patient with advanced refractory prostate cancer has stable disease of longer than 4 months duration. CX-3543 has demonstrated good linearity in PK parameters between the dose cohorts with a terminal half life of approximately 12 hours following the first dose. **Conclusions:** To date, CX-3543 has shown no drug related toxicity and has predictable PKs. No DLTs have yet been observed, and the MTD remains to be defined in this Phase I study. Further enrollment to the planned dose escalation cohorts is ongoing.
2. Kyriakos Papadopoulos, Alain Mita, Alejandro Ricart, David Hufnagel, Donald Northfelt, Daniel Von Hoff, Levan Darjanian, John Lim, Claire Padgett and Robert Marschke; South Texas Accelerated Research Therapeutics, San Antonio, TX, Cancer Therapy and Research Center, San Antonio, TX, Mayo Clinic Arizona, Scottsdale, AZ, Cylene Pharmaceuticals, Inc., San Diego, CA; Pharmacokinetic findings from the phase I study of Quarfloxin (CX-3543): a protein-rDNA quadruplex inhibitor, in patients with advanced solid tumors; AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics-- Oct 22-26, 2007; San Francisco, CA; Abstract B93; **Background:** Ribosomal RNA (rRNA) biosynthesis and subsequent ribosome assembly determine the proliferative state of cells, and these processes are highly amplified in cancer due to mutations in regulatory signaling pathways that control rRNA biogenesis. Quarfloxin, a novel fluoroquinolones derivative, directly inhibits

aberrant rRNA biogenesis in cancer cells by disrupting an essential protein-ribosomal DNA interaction that is over-expressed, thereby selectively triggering apoptotic cell death in tumor cells but not in normal cells. A phase I study of quarfloxin has been completed in patients with solid tumors, including an elucidation of this agent's pharmacokinetic attributes. **Material and Methods:** This phase I study was designed to identify the maximum tolerated dose (MTD), the dose limiting toxicities and the pharmacokinetic profile of quarfloxin when administered as an IV infusion for 5 consecutive days every 21 days, to patients with advanced solid tumors. Serial blood samples were collected for analysis on Day 1 and Day 5 of dosing during the first cycle of drug administration. A twelve hour urine sample was also collected with Day 1 drug administration to determine urinary clearance of quarfloxin. **Results:** A total of 48 patients from 8 escalating dose cohorts of quarfloxin had samples collected for pharmacokinetic analysis. Twenty of these patients were dosed at the maximum tolerated dose level (360 mg/m²). Area under the plasma concentration versus time curve generally increased in proportion with each dose level escalation. Urinary clearance was noted to be consistent throughout all dose levels. Plasma terminal half life was observed to be longer on Day 5 when compared with Day 1, and a trend of increasing plasma terminal half life with each subsequent dose escalation was also evident. The increase in plasma terminal half lives did not result in significant plasma quarfloxin accumulation, and were thought unlikely to be due to saturated elimination. *In vitro* tests using human whole blood revealed that quarfloxin associates reversibly with blood cells, and that whole blood concentration could be up to five fold more than plasma quarfloxin concentration. The pharmacokinetic analysis protocol was amended to include assessments of whole blood and plasma concentration in ten phase I patients at the MTD level of 360 mg/m². At the MTD, Day 5 quarfloxin plasma and whole blood terminal half lives are 75.1 hours and 28.3 hours, respectively. **Conclusions:** The reversible association of quarfloxin with blood cells creates a "reservoir" of drug that is gradually released into plasma, thus extending the plasma terminal half life. This attribute supports drug administration on a weekly basis, and a phase I study of weekly quarfloxin administration is in progress.

3. Abstract of Poster Presentation, American Association of Cancer Research Annual Meeting 2009: Robert F. Marschke, Eleni Andreopoulou, Daniel D. Von Hoff, John K.C. Lim, Claire S. Padgett, Donald W. Northfelt; Front Range Cancer Specialists, Fort Collins, CO; M.D. Anderson Cancer Center, Houston, TX; Mayo Clinic Arizona, Scottsdale, AZ; Cylene Pharmaceuticals, Inc, San Diego, CA; Phase I Clinical Trial of CX-4945: A First-in-Class, Orally Administered Small Molecule Inhibitor of Protein Kinase CK2; **Introduction:** CX-4945 is a novel, orally administered small molecule designed to potently and selectively inhibit protein kinase CK2, a previously unexploited molecular target with well documented roles in many cancers. *In vitro*, CX-4945 selectively kills cancer cells by modulating key survival pathways, resulting in inhibition of proliferation, promotion of apoptosis and cell cycle arrest. Pre-clinically, CX-4945 has demonstrated single-agent potency in suppressing xenograft tumor growth with a wide therapeutic window. The objectives of this phase I study are to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs), to characterize the pharmacokinetics (PKs), and to study the pharmacodynamic effects of CX-4945; **Procedures:** Eligible patients with advanced solid tumors, Castleman's disease or multiple myeloma with progressive disease, or for whom there are no available standard therapies, receive CX-4945 in successive dose cohorts at: 90, 160, 300, 460, 700 and 1000 mg per dose. Oral doses are administered twice daily for twenty-one consecutive days of a four week cycle. Therapy is continued in consenting patients until signs of intolerance to CX-4945 are observed, or there is evidence of advancing disease. Response by RECIST is determined after every 2 cycles. Serial blood and plasma samples are collected on the first and final dosing days of Cycle 1 (i.e., Day 1 and Day 21) for pharmacokinetic analysis and for pharmacodynamic biomarker evaluations (specifically, total and phosphorylated forms of p21 and Akt.); **Results:** Thirteen patients with solid tumors (3-4 patients per cohort, from four separate dose cohorts) have received oral doses of CX-4945. These doses have been well tolerated, with no reported adverse events of grade 3 or higher. CX-4945 has demonstrated general linearity in PK parameters between the dose cohorts, with a terminal half life of approximately 25 hours at steady state; **Conclusions:** To date, CX-4945 has shown no drug related toxicity and has dose proportional PKs. No DLTs have yet been observed, and the MTD remains to be defined in this Phase I study. Further enrollment to the planned dose escalation cohorts is ongoing.

4. Abstract of Poster Presentation, American Association of Cancer Research Annual Meeting 2010; John K.C. Lim, Claire S. Padgett, Robert F. Marschke, Donald W. Northfelt, Eleni Andreopoulou, Daniel D. Von Hoff, Kenna Anderes, Ta Kung Chen, Sean E. O'Brien; Front Range Cancer Specialists, Fort Collins, CO; Mayo Clinic Arizona, Scottsdale, AZ; M.D. Anderson Cancer Center, Houston, TX; Cylene Pharmaceuticals, Inc, San Diego, CA; Utility of Clinical Biomarkers for Detecting Protein Kinase CK2 Inhibition: A Report from the Phase I Trial of CX-4945; **Introduction:** CX-4945 is a first-in-class, orally administered small molecule that potently and selectively inhibits

protein kinase CK2, a previously unexploited molecular target with well documented roles in many cancers. In vitro, CX-4945 selectively kills cancer cells by modulating key survival pathways, resulting in inhibition of cell proliferation, promotion of apoptosis and cell cycle arrest. CK2 hyperactivation of the PI3K/Akt pathway promotes the phosphorylation of several proteins which we have exploited as biomarkers for CX-4945 activity. A validated laser scanning cytometry method has been developed to quantify the phosphorylation of p21 and Akt in cells, and this has been employed to characterize these substrates in circulating blood cells collected from patients in the phase I clinical trial of CX-4945; **Procedures:** Eligible patients with advanced solid tumors with progressive disease, or for whom there are no available standard therapies, were administered CX-4945 in successive dose cohorts using a standard 3x3 design at: 90, 160, 300, 460, 700 and 1000 mg per dose. Oral doses were administered twice daily for twenty-one consecutive days of a four week cycle. Serial plasma samples were collected for pharmacokinetic analysis on the first and final dosing days of Cycle 1 (i.e., Day 1 and Day 21). In addition, whole blood samples were collected at pre-treatment, 4 hours and 8 hours following the first dose of CX-4945 on Day 1 and Day 21, and peripheral blood mononuclear cells (PBMCs) were isolated for pharmacodynamic biomarker evaluations (specifically, total and phosphorylated forms of p21 and Akt.) Plasma samples were also collected at these time points for quantification of plasma IL-6; **Results:** Sixteen patients with advanced solid tumors from four separate dose cohorts have received oral doses of CX-4945 to date, and all patients in the study participated in the collection of PBMCs. Biomarkers from patients in Cohorts 3 and 4 demonstrated changes in their profile consistent with the inhibition of CK2. CX-4945 displays general linearity in PK parameters between the dose cohorts, with a terminal half life of approximately 25 hours at steady state; **Conclusions:** To date, no DLTs have yet been observed, and the MTD remains to be defined in this Phase I study. Early signals suggest a modulation of the biomarker profile consistent with CK2 inhibition. Patient enrollment will continue, to further characterize CX-4945's safety, tolerance, pharmacokinetics and pharmacodynamic effects.